Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemia [0.03%]
双重CDK2和CDK4/6抑制可阻断Rb/E2F信号传导并增强其在急性髓系白血病中的抗白血病活性
Ellen Weisberg,Basudev Chowdhury,Swati Garg et al.
Ellen Weisberg et al.
The cyclin-dependent kinase 6 (CDK6) is a central regulator of cell cycle progression and an important contributor to the development of acute leukemia, particularly in poor prognosis subtypes. Preclinical studies have demonstrated activity...
Bone marrow transplant in aplastic anemia: the horse served us well, but is it still the best ride? [0.03%]
骨髓移植治疗再生障碍性贫血——旧疗法新气象？
Yael Bar On,Ron Ram
Yael Bar On
Not available.
Natural history and early intervention prognostic prediction of neurodegenerative Langerhans cell histiocytosis: insights from the Italian Registry Study. Comment on: "Neurodegenerative Langerhans cell histiocytosis: long-term follow-up of 63 patients from the Italian Registry" [0.03%]
神经退行性朗格汉斯细胞组织细胞增生症的自然病史及早期干预预后预测：意大利登记研究的见解。评论文章：“神经退行性朗格汉斯细胞组织细胞增值症：来自意大利登记的63例患者的长期随访”
Ruijie Li,Zhenghe Liu,Xuan Wu
Ruijie Li
Not available.
Early Intensification with bendamustine supercharge plus brentuximab vedotinfollowing failure to obtain complete metabolic remission after two cycles of ABVD inpatients aged ≤60 years with classic Hodgkin lymphoma. Comment on:"Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkinlymphoma: the LYSA real-world experience&quo [0.03%]
利妥昔单抗 Vedotin 和苯达莫司汀用于治疗接受 ABVD 方案两个周期后仍未获得完全代谢缓解的年轻经典型霍奇金淋巴瘤患者的早期强化治疗。评论：“Brentuximab-vedotin和苯达莫司汀在复发/难治性霍奇金淋巴瘤中的应用：LYSA真实世界体验”
Claudia Giordano,Marco Picardi
Claudia Giordano
Not available.
Diagnostic delay in histiocytic neoplasms and its association with local resource deprivation [0.03%]
组织细胞肿瘤诊断延迟及其与当地医疗资源匮乏的关系
Priya H Marathe,Joshua A Budhu,Anne S Reiner et al.
Priya H Marathe et al.
Not available.
Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed/refractory B-cell non-Hodgkin lymphoma [0.03%]
戈洛塔莫单抗联合泊洛妥珠单抗 vedotin：一种新颖、安全且高度有效的化疗药物，用于治疗儿童复发/难治性B细胞非霍奇金淋巴瘤
Siqi Dong,Meng Wang,Ziyan Luo et al.
Siqi Dong et al.
Not available.
Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma [0.03%]
利妥昔单抗联合甲氨蝶呤新化疗方案治疗中枢神经系统淋巴瘤的Ⅱ期临床研究及来那度胺维持治疗的研究
Ji Yun Lee,Sang-A Kim,Deok-Hwan Yang et al.
Ji Yun Lee et al.
Adults with primary central nervous system lymphoma (PCNSL) who are ineligible for consolidative whole-brain radiotherapy (WBRT) or autologous stem-cell transplantation (ASCT) due to advanced age, comorbidities, or impaired performance stat...
Rooted in reality, living with hope: post-treatment fertility preservation [0.03%]
根植现实，心怀希望——治疗后生育力保护
Rebecca K Chung,Vivian G Oehler
Rebecca K Chung
Not available.
Prognostic impact of Dmax on baseline FDG-PET/CT in newly diagnosed multiple myeloma [0.03%]
新诊断多发性骨髓瘤基线氟脱氧葡萄糖正电子发射断层扫描/X线计算机体层成像Dmax预后价值的影响研究
Léo Raffy,Christèle Etchegaray,Elif Hindie et al.
Léo Raffy et al.
This study aimed to evaluate the prognostic significance of FDG-PET/CT-derived biomarkers, including volumetric and dissemination metrics, in newly diagnosed multiple myeloma (NDMM). A total of 146 NDMM patients who underwent baseline FDG-P...
Sabine Kayser
Sabine Kayser
Not available.